Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atorvastatin + fluoxetine is a combination of two approved small molecule drugs, each with distinct mechanisms of action. Atorvastatin is an HMG-CoA reductase inhibitor (statin) used primarily to lower cholesterol and reduce cardiovascular risk. It works by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant that increases serotonin levels in the brain by inhibiting its reuptake into presynaptic cells, thereby improving mood and treating conditions such as major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder[3][4]. There are no known clinically significant interactions between atorvastatin and fluoxetine when co-administered[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + fluoxetine.